FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLCJanuary 16th 2020
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.
Immunotherapy Brings More Options for Frontline RCC TreatmentDecember 18th 2019
Within approximately 1 year, 3 combination regimens featuring immunotherapy agents were approved by the FDA for the frontline treatment of patients with metastatic renal cell carcinoma (RCC), said Robert J. Motzer, MD.
Utilizing Treatment Free Survival as an Endpoint in ResearchNovember 28th 2019
As immune checkpoint inhibitors begin to reshape how to treat patients with cancer, understanding treatment-free survival as an endpoint in clinical research can better characterize the effects of the treatment.
Providing Immunotherapy Treatment, Support, and Education Under One Roof Proves Beneficial For PatientsNovember 23rd 2019
Canada’s first immunotherapy oncology program provides patient education to not only help them understand the therapy but also mitigate immune-related adverse events.
KATE2 Study Misses Endpoint, Appears Promising for HER2+, PD-L1-Expressing Breast TumorsOctober 24th 2019
At the 2019 ESMO Congress, the phase II KATE2 trial missed its primary endpoint but found promising results for a subgroup of patients with HER2-positive breast cancer with a PD-L1 expression.
Immunotherapy Combo Is Promising in MSI-H Colorectal CancerAugust 26th 2019
The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer (mCRC) whose tumors are microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR)—a population with a historically poor prognosis, said Heinz-Josef Lenz, MD, FACP.